These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Van Allen EM; Miao D; Schilling B; Shukla SA; Blank C; Zimmer L; Sucker A; Hillen U; Foppen MHG; Goldinger SM; Utikal J; Hassel JC; Weide B; Kaehler KC; Loquai C; Mohr P; Gutzmer R; Dummer R; Gabriel S; Wu CJ; Schadendorf D; Garraway LA Science; 2015 Oct; 350(6257):207-211. PubMed ID: 26359337 [TBL] [Abstract][Full Text] [Related]
7. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. Cohen CJ; Gartner JJ; Horovitz-Fried M; Shamalov K; Trebska-McGowan K; Bliskovsky VV; Parkhurst MR; Ankri C; Prickett TD; Crystal JS; Li YF; El-Gamil M; Rosenberg SA; Robbins PF J Clin Invest; 2015 Oct; 125(10):3981-91. PubMed ID: 26389673 [TBL] [Abstract][Full Text] [Related]
8. The neoepitope landscape of breast cancer: implications for immunotherapy. Narang P; Chen M; Sharma AA; Anderson KS; Wilson MA BMC Cancer; 2019 Mar; 19(1):200. PubMed ID: 30832597 [TBL] [Abstract][Full Text] [Related]
9. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Ott PA; Hodi FS; Robert C Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443 [TBL] [Abstract][Full Text] [Related]
10. Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes. Lu T; Wang S; Xu L; Zhou Q; Singla N; Gao J; Manna S; Pop L; Xie Z; Chen M; Luke JJ; Brugarolas J; Hannan R; Wang T Sci Immunol; 2020 Feb; 5(44):. PubMed ID: 32086382 [TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer. Zou XL; Li XB; Ke H; Zhang GY; Tang Q; Yuan J; Zhou CJ; Zhang JL; Zhang R; Chen WY Front Immunol; 2021; 12():689076. PubMed ID: 34992591 [TBL] [Abstract][Full Text] [Related]
12. High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma. Miller A; Asmann Y; Cattaneo L; Braggio E; Keats J; Auclair D; Lonial S; ; Russell SJ; Stewart AK Blood Cancer J; 2017 Sep; 7(9):e612. PubMed ID: 28937974 [TBL] [Abstract][Full Text] [Related]
13. Tumor Microenvironment and Immunotherapy: The Whole Picture Is Better Than a Glimpse. Church SE; Galon J Immunity; 2015 Oct; 43(4):631-3. PubMed ID: 26488814 [TBL] [Abstract][Full Text] [Related]
14. Neoantigen landscape dynamics during human melanoma-T cell interactions. Verdegaal EM; de Miranda NF; Visser M; Harryvan T; van Buuren MM; Andersen RS; Hadrup SR; van der Minne CE; Schotte R; Spits H; Haanen JB; Kapiteijn EH; Schumacher TN; van der Burg SH Nature; 2016 Aug; 536(7614):91-5. PubMed ID: 27350335 [TBL] [Abstract][Full Text] [Related]